Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Géraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Olivier L, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot JM. Géraud A, et al. Among authors: massard c. Eur J Cancer. 2024 May 4;205:114075. doi: 10.1016/j.ejca.2024.114075. Online ahead of print. Eur J Cancer. 2024. PMID: 38733717 Review.
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E. Levy A, et al. Among authors: massard c. Mol Cancer. 2024 Mar 23;23(1):61. doi: 10.1186/s12943-024-01970-8. Mol Cancer. 2024. PMID: 38519913 Free PMC article. Clinical Trial.
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
Bigot L, Sabio J, Poiraudeau L, Annereau M, Menssouri N, Helissey C, Déas O, Aglave M, Ibrahim T, Pobel C, Nobre C, Nicotra C, Ngo-Camus M, Lacroix L, Rouleau E, Tselikas L, Judde JG, Chauchereau A, Bernard-Tessier A, Patrikidou A, Naoun N, Flippot R, Colomba E, Fuerea A, Albiges L, Lavaud P, Massard C, Friboulet L, Fizazi K, Besse B, Scoazec JY, Loriot Y. Bigot L, et al. Among authors: massard c. Eur Urol Oncol. 2023 Oct 26:S2588-9311(23)00226-2. doi: 10.1016/j.euo.2023.10.011. Online ahead of print. Eur Urol Oncol. 2023. PMID: 38433714
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA.
Astier C, Ngo C, Colmet-Daage L, Marty V, Bawa O, Nicotra C, Ngo-Camus M, Italiano A, Massard C, Scoazec JY, Smolenschi C, Ducreux M, Hollebecque A, Postel-Vinay S. Astier C, et al. Among authors: massard c. Exp Hematol Oncol. 2024 Jan 8;13(1):2. doi: 10.1186/s40164-023-00470-7. Exp Hematol Oncol. 2024. PMID: 38191492 Free PMC article.
Antibody drug conjugates in older patients: State of the art.
Rached L, Geraud A, Frelaut M, Ap Thomas Z, Goldschmidt V, Beraud-Chaulet G, Nagera-Lazarovici C, Danlos FX, Henon C, Parisi C, Gazzah A, Bahleda R, Postel Vinay S, Smolenschi C, Hollebecque A, Michot JM, Ribrag V, Loriot Y, Champiat S, Ouali K, Massard C, Ponce Aix S, Bringuier M, Baldini C. Rached L, et al. Among authors: massard c. Crit Rev Oncol Hematol. 2024 Jan;193:104212. doi: 10.1016/j.critrevonc.2023.104212. Epub 2023 Nov 24. Crit Rev Oncol Hematol. 2024. PMID: 38007063 Review.
Pembrolizumab monotherapy for advanced chordoma - Authors' reply.
Blay JY, Penel N, Duffaud F, Bompas E, Massard C, Chevret S. Blay JY, et al. Among authors: massard c. Lancet Oncol. 2023 Oct;24(10):e400. doi: 10.1016/S1470-2045(23)00454-0. Lancet Oncol. 2023. PMID: 37797638 No abstract available.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Among authors: massard c. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Clinical Trial.
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.
Charton E, Baldini C, Fayet Y, Schultz E, Auroy L, Vallier E, Italiano A, Robert M, Coquan E, Isambert N, Moreau P, Touzeau C, Le Tourneau C, Ghrieb Z, Kiladjian JJ, Delord JP, Gomez Roca C, Vey N, Barlesi F, Lesimple T, Penel N, Soria JC, Massard C, Besle S. Charton E, et al. Among authors: massard c. ESMO Open. 2023 Aug;8(4):101610. doi: 10.1016/j.esmoop.2023.101610. Epub 2023 Aug 1. ESMO Open. 2023. PMID: 37536254 Free PMC article.
464 results